NCT04246021View on ClinicalTrials.gov

Use of Intravenous Ferric Carboxymaltose in Treatment of Anemia in Cancer Patients Undergoing Chemotherapy

NACompletedINTERVENTIONAL

Enrollment

84

Participants

Timeline

Start Date

June 15, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions

AnemiaCancer

Interventions

DRUG

Ferric carboxymaltose (FCM)

intravenous iron formulation

Sponsors

Collaborators (1)

Hikma Pharmaceuticals LLC

All Listed Sponsors

collaborator

Hikma Pharmaceuticals LLC

INDUSTRY

lead

King Hussein Cancer Center

OTHER